問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Digestive System Department

Division of Hematology & Oncology

Division of Hematology & Oncology

Chi Mei Hospital, Liouying (在職)

Division of Hematology & Oncology

Hualien Tzu Chi Hospital (在職)

Division of Dermatology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Plastic Surgery

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

更新時間：2024-03-26

陳威宇
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

73Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳威宇

Chi Mei Hospital, Liouying

Division of Hematology & Oncology

List

34Cases

2012-11-30 - 2017-06-30

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-10-15 - 2011-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-08-26 - 2015-05-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-04-01 - 2017-01-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2007-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

  • Condition/Disease

    HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2012-11-30 - 2017-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-06-30 - 2019-06-30

Phase III

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy

  • Condition/Disease

    Previously Undiagnosed Peripheral T-cell Lymphoma

  • Test Drug

    Pralatrexate

Participate Sites
8Sites

Terminated8Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB